NEWS
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
Sage Therapeutics (Nasdaq: SAGE) announced topline results from the Phase 2 LIGHTWAVE Study of dalzanemdor (SAGE-718) in treating mild cognitive impairment and mild dementia in Alzheimer's Disease. The study did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the primary endpoint, which was the WAIS-IV Coding Test score at Day 84.
Key points:
Dalzanemdor was generally well-tolerated with no new safety signals observed
The company does not plan further clinical development of dalzanemdor in Alzheimer's Disease
Topline data from the Phase 2 DIMENSION Study of dalzanemdor in Huntington's Disease is expected later this year
The study involved 174 randomized participants over 12 weeks
No meaningful differences were observed in exploratory endpoints such as RBANS total score or MoCA total score
Key points:
Dalzanemdor was generally well-tolerated with no new safety signals observed
The company does not plan further clinical development of dalzanemdor in Alzheimer's Disease
Topline data from the Phase 2 DIMENSION Study of dalzanemdor in Huntington's Disease is expected later this year
The study involved 174 randomized participants over 12 weeks
No meaningful differences were observed in exploratory endpoints such as RBANS total score or MoCA total score
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2538Followers
107Following
28KVisitors
Follow